PARP抑制和胆固醇生物合成途径调节的协同效应
Anna Rutkowska1, H Christian Eberl1, Thilo Werner1
1Cellzome, GSK, R&D, Heidelberg, Germany.
Cancer research communications
|July 19, 2024
概括
尼拉巴独特地准兰醇合成酶,影响胆固醇生物合成. 将PARP抑制剂与胆固醇通路调节剂 (如他类药物) 结合起来,可以显示出协同杀死癌细胞的效果,这表明了新的治疗策略.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 生物化学 生物化学
背景情况:
- 多 (ADP-ribose) 聚合酶 (PARP) 抑制剂在癌症治疗中至关重要.
- 尼拉帕里布表现出独特的多药理学,而不是在其他PARP抑制剂中看到的.
- 胆固醇生物合成与各种癌症类型有关.
研究的目的:
- 为了研究niraparib多药学的分子机制.
- 探索将PARP抑制剂与胆固醇生物合成途径调节器结合在一起的治疗潜力.
主要方法:
- PARP 抑制剂的多原子分子表征.
- 使用癌细胞系和患者衍生卵巢瘤器官的体外研究.
- 药理上抑制了兰醇合成酶 (LSS) 和3-基-3-甲基氨酸-共酶A减少酶 (HMGCR).
主要成果:
- 尼拉帕里布与兰醇合成酶 (LSS) 相互作用,激活24,25-氧醇分离路径.
- 将LSS抑制剂与非LSS结合的PARP抑制剂 (例如,olaparib) 结合在一起,显示了添加性癌细胞杀死.
- 同时抑制PARP和胆固醇生物合成 (使用他类药物) 证明了协同杀死瘤细胞.
结论:
- 尼拉帕里布与LSS的独特相互作用提供了一种独特的治疗方法.
- 联合抑制PARP和胆固醇生物合成途径为增强抗瘤疗效提供了一个有希望的策略.
- 需要进一步调查,以评估这些发现的翻译相关性.
相关概念视频
Interactions Between Signaling Pathways
6.3K
Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
6.3K
Combined Effects of Drugs: Synergism
3.8K
Synergism is a useful mechanism where combining two or more drugs is more effective than each constituent used alone. Such combinations are also called supra-additive interactions. The drugs collectively enhance the final therapeutic effect by acting on different targets. Another advantage is that the low dose of each constituent drug is sufficient to achieve the desired effect. This helps reduce the duration of therapy and lower the adverse effects of these drugs.
Such synergistic combinations...
Such synergistic combinations...
3.8K
Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance
115
The elimination half-life and drug clearance of drugs following nonlinear kinetics can vary with dosage. The Michaelis-Menten parameters and drug concentration influence these factors. As the dose increases, the elimination half-life tends to lengthen, resulting in a reduction in clearance and a disproportionately larger area under the curve. The total clearance can be derived from the Michaelis-Menten equation for drugs following a one-compartment model.
A study on guinea pigs examined the...
A study on guinea pigs examined the...
115
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
621
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
621
Feedback Inhibition
53.8K
Biochemical reactions are occurring constantly in cells, converting starting substances to different products, usually with the help of enzymes that speed the reactions. Without enzymes, it would take far too long for most reactions to occur to be useful to the cell!
53.8K
Inhibition of Cdk Activity
4.7K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.7K


